To examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors. We analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n =...
Prostate cancer is the second leading cause of cancer-related deaths among U.S. men. While cannabis and classic psychedelics gain attention for symptom management in oncology, their associations with prostate cancer remain unexplored. This study evaluates associations between lifetime classic psychedelic and cannabis use with prostate cancer diagnoses among older U.S. adults using 2015-2019...
e22518 Background: Classic psychedelics (Peyote, Psilocybin, Mescaline, and LSD) are re-emerging in the oncology toolbox. Peyote is the oldest known psychedelic, yet underexplored in clinical research. Preclinical studies suggest its extract stimulates lymphocyte proliferation, kills tumor cells, and may regulate sleep. This study aims to estimate the prevalence of classic psychedelic use among...